Literature DB >> 16083825

Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.

Philip Bierman1, Pierre Giglio.   

Abstract

The diagnosis of lymphoma of the central nervous system (CNS) has been facilitated by advances in neuroimaging and laboratory analysis of cerebrospinal fluid. The most common form of central nervous system CNS involvement in non-Hodgkin's lymphoma (NHL) is leptomeningeal disease. After a diagnosis is established, the use of intrathecal or systemic chemotherapy and radiotherapy can improve survival and palliate symptoms. High-dose systemic chemotherapy with hematopoietic stem cell transplantation is an important treatment option at central nervous system relapse of NHL and for primary CNS lymphoma. The prognosis for disease-free survival and cure is better for patients who have treatment of CNS disease before transplantation than for patients who have active central nervous system disease at the time of transplant.

Entities:  

Mesh:

Year:  2005        PMID: 16083825     DOI: 10.1016/j.hoc.2005.05.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  19 in total

1.  My treatment approach to patients with diffuse large B-cell lymphoma.

Authors:  James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B-cell lymphoma.

Authors:  Man Fai Law; Hay Nun Chan; Ho Kei Lai; Chung Yin Ha; Celia Ng; Yiu Ming Yeung; Sze Fai Yip
Journal:  Mol Clin Oncol       Date:  2015-04-16

4.  Central nervous system Hodgkin lymphoma: case report and review of the literature.

Authors:  Sara Torgerson; Horatiu Olteanu; Matthew Tinguely; Timothy S Fenske
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

5.  Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.

Authors:  Timothy S Saunders; Sarah Anis; Yelena Doych; Anna Moran; J Steve Hou; Xiaoli Chen; Myron Yanoff
Journal:  Digit J Ophthalmol       Date:  2010-07-29

6.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Authors:  Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

Review 7.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 8.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

9.  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Authors:  Agnieszka Korfel; Thomas Elter; Eckhard Thiel; Matthias Hänel; Robert Möhle; Roland Schroers; Marcel Reiser; Martin Dreyling; Jan Eucker; Christian Scholz; Bernd Metzner; Alexander Röth; Josef Birkmann; Uwe Schlegel; Peter Martus; Gerard Illerhaus; Lars Fischer
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

10.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.